Not a threat but a potential customer. Fuji is the threat to them with their GvHD solution using our Tech to produce it. Fuji will have to do human phase II & III testing off their own bat and will still be chasing MSB who I think have passed Phase III and have a product to market now.
We should be in negotiations with MSB on their other product lines that have passed phase I and II trials to use our platform. Bring on the MOU for their non-GvHD treatments using our platform.
Not a threat but a potential customer. Fuji is the threat to...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22209 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 36715 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |